BOSTON, MA, Dash Bio, a preclinical and clinical bioanalysis company reinventing the speed and scalability of drug development, has raised an additional $11 million in funding.
Dash Bio, a preclinical and clinical bioanalysis company reinventing the speed and scalability of drug development, announced it has raised an additional $11 million in funding, bringing its total raised to $17.5 million. The new financing was led by The Aligned Fund, with participation from Freestyle Capital, Cybernetix Ventures, Swift Ventures, LifeX Ventures, Drive Capital, and others.
(c) by Massinvestor, Inc. For contact info, please check out our
about page.
